Further investigations of lupus anticoagulant interference in a functional assay for tissue factor pathway inhibitor

Thrombosis Research

Volumn 87, Issue 2, 1997, Pages 245-249

  Adams, Murray J ^a   Oostryck, Robert ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

Lupus anticoagulant; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

LUPUS ANTICOAGULANT; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BINDING AFFINITY; ENZYME ASSAY; HEMOSTASIS; HUMAN; HUMAN CELL; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; PROTHROMBIN TIME; TECHNIQUE; THROMBOPLASTIN TIME; THROMBOSIS;

BIOLOGICAL ASSAY; CROSS REACTIONS; FACTOR XA; HUMANS; LIPOPROTEINS; LUPUS COAGULATION INHIBITOR;

EID: 0030806233     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00124-2     Document Type: Article

References (13)

1. BROZE G.J., WARREN L.A., NOVOTNY W.F., HIGUCHI D.A., GIRARD J.J., MILETICH J.P. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 71:1988;335-343.
2. BAJAJ M.S., RANA S.V., WYSOLMERSKI R.B., BAJAJ S.B. Inhibition of the FVIIa-tissue complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J. Clin. Invest. 79:1987;1874-1878.
3. JACOBSEN E.M., SANDSET P.M., WISLØFF F. Lupus anticoagulant and a functional assay for tissue factor pathway inhibitor. Thrombosis Research. 83:1996;339-340.
4. McNEIL H.P., CHESTERMAN C.N., KRILIS S.A. Anticardiolipin antibodies and lupus anticoagulant comprise separate antibody subgroups with different phospholipid binding characteristics. Br. J. Haem. 73:1989;506-513.
5. TRIPLETT D.A. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thrombosis Research. 78:1995;1-31.
6. TRIPLETT D.A. Protean clinical presentation of antiphospholipid-protein antibodies (APA). Thromb Haemost. 74:1995;329-337.
7. ADAMS M.J., DUNSTAN R.A., OOSTRYCK R. Interference by lupus anticoagulant in a functional assay for tissue factor pathway inhibitor. Thrombosis Research. 80:1995;435-440.
8. SANDSET P.M., LARSEN M.L., ABILDGAARD U., LINDAHL A.K., ØDEGAARD O.R. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagulation and Fibrinolysis. 2:1991;425-433.
9. EXNER T., TRIPLETT D.A., TABERNER D. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemost. 65:1991;320-322.
10. HJORT P.F. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand J Clin Lab Invest. 9:1957;1-173.
11. NEMERSON Y. Characterisation and lipid requirements of coagulant proteins extracted from lung and brain. J Clin Invest. 48:1969;332-337.
12. ARNOUT J., VANRUSSELT M., HUYBRECHTS E., VERMYLEN J. Optimisation of the dilute PT for the detection of the lupus anticoagulant by use of a recombinant tissue factor. Br J Haem. 87:1994;94-99.
13. BERRETTINI M., MALASPINA M., PARISE P., LUCARELLLI G., KISIEL W., NENCI G.G. A simple chromogenic substrate assay of tissue factor pathway inhibitor in plasma and serum. Am J Clin Path. 103:1995;391-395.